For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

The combined regimen achieved a higher remission rate than calorie restriction alone in people with overweight or obesity and ...

AstraZeneca's Farxiga reduced the risk of ... The study showed that treatment with Farxiga (dapagliflozin) led to an 18% reduction in cardiovascular death or worsening heart failure in patients ...

As part of the pact, Sun Pharma will sell AstraZeneca's dapagliflozin, a Type 2 diabetes medicine, under brand name Oxra. AstraZeneca India markets dapagliflozin under the brand name Forxiga.

The FDA approved dapagliflozin (Farxiga) for glycemic control in children ages 10 years and older with type 2 diabetes, based on results from the phase III T2NOW trial, AstraZeneca announced.

Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing ...

The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin.